Top

Published in:

01-09-2009 | Original Paper

Sendai viral vector mediated angiopoietin-1 gene transfer for experimental ischemic limb disease

Authors: Jianhua Huang, Makoto Inoue, Mamoru Hasegawa, Kei Tomihara, Toshihiro Tanaka, Jiahua Chen, Hirofumi Hamada

Published in: Angiogenesis | Issue 3/2009

Abstract

Sendai virus vector is emerging as a promising vector for gene therapy, and angiopoietin-1 (Ang-1) has been reported to improve the blood flow recovery in the ischemic limb or heart. In this study, we constructed a human Ang-1-expressing Sendai viral vector (SeVhAng-1) and injected it into the ischemic limb of rats. We found that SeVhAng-1 improved the blood flow recovery and increased the capillary density of the ischemic limb, compared with the controls. We also found that SeVhAng-1 increased p-Akt during the early period of limb ischemia, and decreased apoptosis in ischemic limb. It suggests that SeVhAng-1 may serve as a potential therapeutic tool in ischemic limb disease.

Baumgartner I, Pieczek A, Manor O et al (1998) Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 97:1114–1123PubMed

Baumgartner I, Rauh G, Pieczek A et al (2000) Lower-extremity edema associated with gene transfer of naked DNA encoding vascular endothelial growth factor. Ann Intern Med 132:880–884PubMed

Takeshita S, Zheng LP, Brogi E et al (1994) Therapeutic angiogenesis: a single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest 93:662–670. doi:10.1172/JCI117018 PubMedCrossRef

Tsurumi Y, Kearney M, Chen D et al (1997) Treatment of acute limb ischemia by intramuscular injection of vascular endothelial growth factor gene. Circulation 96(suppl II):II-382–II-388

Rajagopalan S, Mohler ER 3rd, Lederman RJ et al (2003) Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 108:1933–1938. doi:10.1161/01.CIR.0000093398.16124.29 PubMedCrossRef

Davis S, Aldrich TH, Jones PF et al (1996) Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 87:1161–1169. doi:10.1016/S0092-8674(00)81812-7 PubMedCrossRef

Gale NW, Yancopoulos GD (1999) Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. Genes Dev 13:1055–1066. doi:10.1101/gad.13.9.1055 PubMedCrossRef

Suri C, Jones PF, Patan S et al (1996) Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 87:1171–1180. doi:10.1016/S0092-8674(00)81813-9 PubMedCrossRef

Suri C, McClain J, Thurston G et al (1998) Increased vascularization in mice overexpressing angiopoietin-1. Science 282:468–471. doi:10.1126/science.282.5388.468 PubMedCrossRef

10.

Shyu KG, Manor O, Magner M et al (1998) Direct intramuscular injection of plasmid DNA encoding angiopoietin-1 but not angiopoietin-2 augments revascularization in the rabbit ischemic hindlimb. Circulation 98:2081–2087PubMed

11.

Yamauchi A, Ito Y, Morikawa M et al (2003) Pre-administration of angiopoietin-1 followed by VEGF induces functional and mature vascular formation in a rabbit ischemic model. J Gene Med 5:994–1004. doi:10.1002/jgm.439 PubMedCrossRef

12.

Takahashi K, Ito Y, Morikawa M et al (2003) Adenoviral-delivered angiopoietin-1 reduces the infarction and attenuates the progression of cardiac dysfunction in the rat model of acute myocardial infarction. Mol Ther 8:584–592. doi:10.1016/S1525-0016(03)00230-2 PubMedCrossRef

13.

Bitzer M, Armeanu S, Lauer UM et al (2003) Sendai virus vectors as an emerging negative-strand RNA viral vector system. J Gene Med 5:543–553. doi:10.1002/jgm.426 PubMedCrossRef

14.

Yonemitsu Y, Kitson C, Ferrari S et al (2000) Efficient gene transfer to airway epithelium using recombinant Sendai virus. Nat Biotechnol 18:970–973. doi:10.1038/79463 PubMedCrossRef

15.

Masaki I, Yonemitsu Y, Komori K et al (2001) Recombinant Sendai virus-mediated gene transfer to vasculature: a new class of efficient gene transfer vector to the vascular system. FASEB J 15:1294–1296PubMed

16.

Li HO, Zhu YF, Asakawa M et al (2000) Cytoplasmic RNA vector derived from non-transmissible Sendai virus with efficient gene transfer and expression. J Virol 74:6564–6569. doi:10.1128/JVI.74.14.6564-6569.2000 PubMedCrossRef

17.

Ikeda Y, Goto Y, Yonemitsu Y et al (2003) Simian immunodeficiency virus-based lentivirus vector for retinal gene transfer: a preclinical safety study in adult rats. Gene Ther 10:1161–1169. doi:10.1038/sj.gt.3301973 PubMedCrossRef

18.

Okano S, Yonemitsu Y, Nagata S et al (2003) Recombinant Sendai virus vectors for activated T lymphocytes. Gene Ther 10:1381–1391. doi:10.1038/sj.gt.3301998 PubMedCrossRef

19.

Jin CH, Kusuhara K, Yonemitsu Y et al (2003) Recombinant Sendai virus provides a highly efficient gene transfer into human cord blood-derived hematopoietic stem cells. Gene Ther 10:272–277. doi:10.1038/sj.gt.3301877 PubMedCrossRef

20.

Hasan MK, Kato A, Shioda T et al (1997) Creation of an infectious recombinant Sendai virus expressing the firefly luciferase gene from the 3′ proximal first locus. J Gen Virol 78:2813–2820PubMed

21.

Fuerst TR, Niles EG, Studier FW et al (1986) Eukaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase. Proc Natl Acad Sci USA 83:8122–8126. doi:10.1073/pnas.83.21.8122 PubMedCrossRef

22.

Kato A, Sakai Y, Shioda T et al (1996) Initiation of Sendai virus multiplication from transfected cDNA or RNA with negative or positive sense. Genes Cells 1:569–579. doi:10.1046/j.1365-2443.1996.d01-261.x PubMedCrossRef

23.

Seifert FC, Banker M, Lane B et al (1985) An evaluation of resting arterial ischemia models in the rat hind limb. J Cardiovasc Surg (Torino) 26:502–508

24.

Huang J, Ito Y, Morikawa M et al (2003) Bcl-xL gene transfer protects the heart against ischemia/reperfusion injury. Biochem Biophys Res Commun 311:64–70. doi:10.1016/j.bbrc.2003.09.160 PubMedCrossRef

25.

Shimpo M, Ikeda U, Maeda Y et al (2002) AAV-mediated VEGF gene transfer into skeletal muscle stimulates angiogenesis and improves blood flow in a rat hindlimb ischemia model. Cardiovasc Res 53:993–1001. doi:10.1016/S0008-6363(01)00546-6 PubMedCrossRef

26.

Iwadate Y, Inoue M, Saegusa T et al (2005) Recombinant Sendai virus vector induces complete remission of established brain tumors through efficient interleukin-2 gene transfer in vaccinated rats. Clin Cancer Res 11:3821–3827. doi:10.1158/1078-0432.CCR-04-1485 PubMedCrossRef

27.

Inoue M, Tokusumi Y, Ban H et al (2004) Recombinant Sendai virus vectors deleted in both the matrix and the fusion genes: efficient gene transfer with preferable properties. J Gene Med 6:1069–1081. doi:10.1002/jgm.597 PubMedCrossRef

28.

Matsunaga T, Warltier DC, Tessmer J et al (2003) Expression of VEGF and angiopoietins-1 and -2 during ischemia-induced coronary angiogenesis. Am J Physiol Heart Circ Physiol 285:H352–H358PubMed

29.

Papapetropoulos A, Garcia-Cardena G, Dengler TJ et al (1999) Direct actions of angiopoietin-1 on human endothelium: evidence for network stabilization, cell survival, and interaction with other angiogenic growth factors. Lab Invest 79:213–223PubMed

30.

Holash J, Maisonpierre PC, Compton D et al (1999) Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284:1994–1998. doi:10.1126/science.284.5422.1994 PubMedCrossRef

31.

Kwak HJ, So JN, Lee SJ et al (1999) Angiopoietin-1 is an apoptosis survival factor for endothelial cells. FEBS Lett 448:249–253. doi:10.1016/S0014-5793(99)00378-6 PubMedCrossRef

32.

Kim I, Kim HG, So JN et al (2000) Angiopoietin-1 regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Circ Res 86:24–29PubMed

33.

Dallabrida SM, Ismail N, Oberle JR et al (2005) Angiopoietin-1 promotes cardiac and skeletal myocyte survival through integrins. Circ Res 96:e8–e24. doi:10.1161/01.RES.0000158285.57191.60 PubMedCrossRef

Title: Sendai viral vector mediated angiopoietin-1 gene transfer for experimental ischemic limb disease
Authors: Jianhua Huang
Makoto Inoue
Mamoru Hasegawa
Kei Tomihara
Toshihiro Tanaka
Jiahua Chen
Hirofumi Hamada
Publication date: 01-09-2009
Publisher: Springer Netherlands
Published in: Angiogenesis / Issue 3/2009
Print ISSN: 0969-6970
Electronic ISSN: 1573-7209
DOI: https://doi.org/10.1007/s10456-009-9144-6

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2009

Shear stress-induced transcriptional regulation via hybrid promoters as a potential tool for promoting angiogenesis

Chloride intracellular channel 4 is involved in endothelial proliferation and morphogenesis in vitro

A highly selective, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor has potent activity in vitro and in vivo

Single and combined effects of αvβ3- and α5β1-integrins on capillary tube formation in a human fibrinous matrix

Wnt2 acts as an angiogenic growth factor for non-sinusoidal endothelial cells and inhibits expression of stanniocalcin-1

Analysis of PPARα-dependent and PPARα-independent transcript regulation following fenofibrate treatment of human endothelial cells

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials